Metrics as of 10/17/2026, 07:03 AM (Berlin time), refresh in progress.
Zoetis Stock
Zoetis Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Kristin C. Peck
- Employees
- 14,500
- Market cap
- $32.8 B
- IPO
- 01/02/2013
Zoetis Inc. is a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Headquartered in Parsippany, USA, the company was established in 1952 and employs approximately 14,500 people. Its comprehensive…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Zoetis stock: price history
1D
+1.1%
1W
+6.0%
1M
+8.7%
6M
-35.2%
YTD
-37.0%
1Y
-44.6%
2Y
-59.2%
5Y
-60.8%
10Y
+58.1%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~109% stronger price swings than usual
Zoetis stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Zoetis
Analyst assessment of Zoetis
PRICE TARGET LOW
US$74.00
CONSENSUS
US$85.43
MEDIAN
US$85.00
PRICE TARGET HIGH
US$95.00
1
STRONG BUY
14
BUY
17
HOLD
0
SELL
0
STRONG SELL
32
TOTAL · Hold
As of: 25/08/2026
Zoetis stock metrics
P/E
13.05
P/B
10.52
EV/EBITDA
10.15
RETURN ON EQUITY
22.0%
NET MARGIN
28.0%
DEBT/EQUITY
2.93
DIVIDEND YIELD
2.6%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
412,372,361
AVG. DAILY VOLUME (30D)
4,529,840
Insider transactions (SEC)
FULLER JULIE
FULLER JULIE
DAMELIO FRANK A
MCCALLISTER MICHAEL B
Stetter Mark
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +1.1%
Forums (Reddit)
Institutional holders
Dividends
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Zoetis stock
What does Zoetis do?
Zoetis Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Kristin C. Peck, the company employs around 14,500 people.
The IPO was on 01/02/2013; the stock trades on NYSE under the ticker ZTS.
What do analysts say about Zoetis stock?
32 analysts rate the stock, the consensus is Hold (as of 25/08/2026).
The average price target is US$85.43, ranging from US$74.00 to US$95.00, with a median of US$85.00.
This is an external assessment, not a statement by Market Jury.
When does Zoetis report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 109% stronger than usual.
Does Zoetis pay a dividend?
Yes. The last dividend was US$0.53 per share, ex-date 30/10/2026, paid on 01/12/2026.
The dividend yield is 2.6% (as of 30/06/2026).
Which stocks are comparable to Zoetis?
Comparable stocks include Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences, Amphastar Pharmaceuticals and Aquestive Therapeutics.
How can I get Zoetis stock analyzed?
Clicking "Analyze stock" lets five strategies assess Zoetis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.